Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.

CONCLUSIONS: ER+/HER2- patients most likely to benefit from NAC are those with PR- and HP tumors. Patients with ILC are unlikely to downstage in the breast or axilla compared with IDC. The use of these criteria can assist in defining the initial treatment approach. PMID: 28560596 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28560596?dopt=Abstract

Source: Ann Oncol - May 30, 2017 Category: Cancer & Oncology Authors: Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, Morrow M Tags: Ann Surg Oncol Source Type: research